

Global CIS Insulin Market Size study, by Product, Type (Human Insulin, Insulin Analog), Application (Type 1 Diabetes), Distribution Channel and Regional Forecasts 2022-2032

<https://marketpublishers.com/r/G57F79D1A96FEN.html>

Date: May 2025

Pages: 285

Price: US\$ 3,750.00 (Single User License)

ID: G57F79D1A96FEN

Abstracts

The Global CIS Insulin Market is valued approximately at USD 3.05 billion in 2023 and is anticipated to grow with a steady yet sustainable growth rate of more than 5.60% over the forecast period 2024-2032. As the prevalence of diabetes continues to surge across Central and South Asia, Eastern Europe, and parts of the Caucasus, the demand for life-sustaining therapies like insulin has witnessed a significant upturn. The CIS region, with its diverse socio-economic profile and aging population, has become a critical geography for insulin manufacturers looking to balance accessibility with innovation. Moreover, the shift towards insulin analogs—engineered for greater efficacy and minimized side effects—is reshaping therapeutic preferences, making next-generation solutions more viable than ever in healthcare infrastructures that are modernizing rapidly.

Amid this evolving backdrop, the insulin market is being powered by a robust convergence of technological advancements and public healthcare initiatives. Increasing investments in cold chain logistics and healthcare digitization across countries like Russia, Kazakhstan, and Belarus are removing traditional distribution barriers that long hindered insulin accessibility. Furthermore, a shift in government procurement policies has created a conducive environment for both multinational players and regional manufacturers to scale operations while meeting stringent compliance standards. The penetration of biosimilar insulins has also introduced a price-competitive landscape that's pushing innovation while ensuring affordability for millions.

However, despite the promising trajectory, certain challenges continue to hamper

market acceleration. Regulatory complexities, particularly in harmonizing local approvals with international clinical data, remain a persistent bottleneck. Many countries in the CIS bloc face systemic issues in terms of uneven healthcare access across rural and urban sectors, creating market fragmentation. Moreover, the relatively slow adoption of insulin pumps and digital glucose monitoring systems signals an infrastructural gap that needs to be bridged to truly modernize diabetes management. These limitations, if strategically addressed, could open up immense untapped potential across underserved demographics.

Fueling this outlook is the growing role of public-private partnerships and government-led initiatives aimed at enhancing diabetes care. Multilateral collaborations between health ministries and global institutions such as the WHO and IDF are supporting structured awareness programs, improving early diagnosis, and ensuring consistent insulin supply chains. The move toward localized manufacturing, particularly in countries like Uzbekistan and Armenia, is enabling the establishment of self-reliant healthcare ecosystems. Moreover, the rising consumer inclination towards value-based healthcare and personalized treatments is compelling industry stakeholders to design patient-centric delivery formats and novel formulations.

Regionally, Europe accounted for the largest market share in 2023, driven by its strong pharmaceutical R&D base, favorable reimbursement landscape, and widespread diabetes screening initiatives. Countries like Russia and Ukraine are spearheading clinical trials for ultra-long-acting insulin variants and smart insulin delivery systems. On the other hand, Asia Pacific is anticipated to witness the fastest CAGR during the forecast timeline, buoyed by expanding healthcare coverage, growing diabetes burden, and increasing urbanization in key markets like Kazakhstan, Turkmenistan, and Mongolia. Latin America and the Middle East are also emerging as promising frontiers, leveraging regional trade pacts and international funding to bolster insulin availability and affordability.

Major market player included in this report are:

Novo Nordisk A/S

Sanofi S.A.

Eli Lilly and Company

Biocon Ltd.

Wockhardt Ltd.

Julphar (Gulf Pharmaceutical Industries)

Merck & Co., Inc.

Boehringer Ingelheim

Pfizer Inc.

Gan & Lee Pharmaceuticals

Ypsomed Holding AG

Oramed Pharmaceuticals Inc.

Gedeon Richter Plc

Dongbao Enterprise Group Co., Ltd.

Geropharm

The detailed segments and sub-segment of the market are explained below:

By Product

Rapid-acting Insulin

Long-acting Insulin

Short-acting Insulin

Premixed Insulin

Intermediate-acting Insulin

By Type

Human Insulin

Insulin Analog

By Application

Type 1 Diabetes

By Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

Rest of Europe

Asia Pacific

China

India

Japan

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East & Africa

Saudi Arabia

South Africa

Rest of Middle East & Africa

Years considered for the study are as follows:

Historical year – 2022

Base year – 2023

Forecast period – 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.

Annualized revenues and regional level analysis for each market segment.

Detailed analysis of geographical landscape with country-level analysis of major regions.

Competitive landscape with information on major players in the market.

Analysis of key business strategies and recommendations on future market approach.

Analysis of competitive structure of the market.

Demand side and supply side analysis of the market.

Contents

CHAPTER 1. GLOBAL CIS INSULIN MARKET EXECUTIVE SUMMARY

- 1.1. Global CIS Insulin Market Size & Forecast (2022–2032)
- 1.2. Regional Summary
- 1.3. Segmental Summary
 - 1.3.1. By Product
 - 1.3.2. By Type
 - 1.3.3. By Application
 - 1.3.4. By Distribution Channel
- 1.4. Key Trends
- 1.5. Recession Impact
- 1.6. Analyst Recommendation & Conclusion

CHAPTER 2. GLOBAL CIS INSULIN MARKET DEFINITION AND RESEARCH ASSUMPTIONS

- 2.1. Research Objective
- 2.2. Market Definition
- 2.3. Research Assumptions
 - 2.3.1. Inclusion & Exclusion
 - 2.3.2. Limitations
 - 2.3.3. Supply Side Analysis
 - 2.3.3.1. Availability
 - 2.3.3.2. Infrastructure
 - 2.3.3.3. Regulatory Environment
 - 2.3.3.4. Market Competition
 - 2.3.3.5. Economic Viability (Customer's Perspective)
 - 2.3.4. Demand Side Analysis
 - 2.3.4.1. Regulatory Frameworks
 - 2.3.4.2. Technological Advancements
 - 2.3.4.3. Environmental Considerations
 - 2.3.4.4. Customer Awareness & Acceptance
- 2.4. Estimation Methodology
- 2.5. Years Considered for the Study
- 2.6. Currency Conversion Rates

CHAPTER 3. GLOBAL CIS INSULIN MARKET DYNAMICS

Global CIS Insulin Market Size study, by Product, Type (Human Insulin, Insulin Analog), Application (Type 1 Di...

3.1. Market Drivers

- 3.1.1. Surging Prevalence of Diabetes across CIS Nations
- 3.1.2. Shift toward Long-Acting and Ultra-Rapid Insulin Analogs
- 3.1.3. Expansion of Cold-Chain Logistics and Distribution Networks
- 3.1.4. Growing Public and Private Healthcare Expenditure

3.2. Market Challenges

- 3.2.1. Regulatory Heterogeneity and Approval Delays
- 3.2.2. Fragmented Healthcare Access in Rural vs Urban Areas
- 3.2.3. High Cost of Advanced Insulin Delivery Systems
- 3.2.4. Slow Adoption of Digital Monitoring and Pump Technologies

3.3. Market Opportunities

- 3.3.1. Introduction of Biosimilar and Biobetters
- 3.3.2. Localization of Manufacturing in Emerging CIS Markets
- 3.3.3. Integration of Value-Based Healthcare Models

CHAPTER 4. GLOBAL CIS INSULIN MARKET INDUSTRY ANALYSIS

4.1. Porter's Five Forces Model

- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's Model
- 4.1.7. Porter's Five Forces Impact Analysis

4.2. PESTEL Analysis

- 4.2.1. Political
- 4.2.2. Economic
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal

4.3. Top Investment Opportunities

4.4. Top Winning Strategies

4.5. Disruptive Trends

4.6. Industry Expert Perspective

4.7. Analyst Recommendation & Conclusion

CHAPTER 5. GLOBAL CIS INSULIN MARKET SIZE & FORECASTS BY PRODUCT, 2022–2032

- 5.1. Segment Dashboard
- 5.2. Rapid-Acting Insulin Revenue Trend, 2022 & 2032
- 5.3. Long-Acting Insulin Revenue Trend, 2022 & 2032
- 5.4. Short-Acting Insulin Revenue Trend, 2022 & 2032
- 5.5. Premixed Insulin Revenue Trend, 2022 & 2032
- 5.6. Intermediate-Acting Insulin Revenue Trend, 2022 & 2032

CHAPTER 6. GLOBAL CIS INSULIN MARKET SIZE & FORECASTS BY TYPE, 2022–2032

- 6.1. Segment Dashboard
- 6.2. Human Insulin Revenue Trend, 2022 & 2032
- 6.3. Insulin Analog Revenue Trend, 2022 & 2032

CHAPTER 7. GLOBAL CIS INSULIN MARKET SIZE & FORECASTS BY APPLICATION & DISTRIBUTION CHANNEL, 2022–2032

- 7.1. By Application – Type 1 Diabetes Revenue Trend, 2022 & 2032
- 7.2. By Distribution Channel
 - 7.2.1. Hospital Pharmacies Revenue Trend, 2022 & 2032
 - 7.2.2. Retail Pharmacies Revenue Trend, 2022 & 2032
 - 7.2.3. Online Pharmacies Revenue Trend, 2022 & 2032

CHAPTER 8. GLOBAL CIS INSULIN MARKET SIZE & FORECASTS BY REGION, 2022–2032

- 8.1. North America Market
 - 8.1.1. U.S. Market
 - 8.1.2. Canada Market
- 8.2. Europe Market
 - 8.2.1. UK Market
 - 8.2.2. Germany Market
 - 8.2.3. France Market
 - 8.2.4. Spain Market
 - 8.2.5. Italy Market
 - 8.2.6. Rest of Europe Market

8.3. Asia Pacific Market

- 8.3.1. China Market
- 8.3.2. India Market
- 8.3.3. Japan Market
- 8.3.4. Australia Market
- 8.3.5. South Korea Market
- 8.3.6. Rest of Asia Pacific Market

8.4. Latin America Market

- 8.4.1. Brazil Market
- 8.4.2. Mexico Market
- 8.4.3. Rest of Latin America Market

8.5. Middle East & Africa Market

- 8.5.1. Saudi Arabia Market
- 8.5.2. South Africa Market
- 8.5.3. Rest of Middle East & Africa Market

CHAPTER 9. COMPETITIVE INTELLIGENCE

9.1. Key Company SWOT Analysis

- 9.1.1. Novo Nordisk A/S
- 9.1.2. Sanofi S.A.
- 9.1.3. Eli Lilly and Company

9.2. Top Market Strategies

9.3. Company Profiles

- 9.3.1. Novo Nordisk A/S
 - 9.3.1.1. Key Information
 - 9.3.1.2. Overview
 - 9.3.1.3. Financial (Subject to Data Availability)
 - 9.3.1.4. Product Summary
 - 9.3.1.5. Market Strategies
- 9.3.2. Sanofi S.A.
- 9.3.3. Eli Lilly and Company
- 9.3.4. Biocon Ltd.
- 9.3.5. Wockhardt Ltd.
- 9.3.6. Julphar (Gulf Pharmaceutical Industries)
- 9.3.7. Merck & Co., Inc.
- 9.3.8. Boehringer Ingelheim
- 9.3.9. Pfizer Inc.
- 9.3.10. Gan & Lee Pharmaceuticals

- 9.3.11. Ypsomed Holding AG
- 9.3.12. Oramed Pharmaceuticals Inc.
- 9.3.13. Gedeon Richter Plc
- 9.3.14. Dongbao Enterprise Group Co., Ltd.
- 9.3.15. Geropharm

CHAPTER 10. RESEARCH PROCESS

- 10.1. Research Process
 - 10.1.1. Data Mining
 - 10.1.2. Analysis
 - 10.1.3. Market Estimation
 - 10.1.4. Validation
 - 10.1.5. Publishing
- 10.2. Research Attributes

I would like to order

Product name: Global CIS Insulin Market Size study, by Product, Type (Human Insulin, Insulin Analog), Application (Type 1 Diabetes), Distribution Channel and Regional Forecasts 2022-2032

Product link: <https://marketpublishers.com/r/G57F79D1A96FEN.html>

Price: US\$ 3,750.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G57F79D1A96FEN.html>